Campbell & CO Investment Adviser LLC purchased a new position in Intersect ENT Inc (NASDAQ:XENT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,317 shares of the medical equipment provider’s stock, valued at approximately $228,000.

Several other institutional investors also recently bought and sold shares of XENT. Legal & General Group Plc boosted its stake in Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the period. Voya Investment Management LLC boosted its stake in Intersect ENT by 9.7% during the second quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock valued at $356,000 after buying an additional 1,128 shares during the period. Rhumbline Advisers boosted its stake in Intersect ENT by 5.9% during the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock valued at $822,000 after buying an additional 1,625 shares during the period. EAM Investors LLC boosted its stake in Intersect ENT by 1.1% during the third quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock valued at $5,117,000 after buying an additional 1,776 shares during the period. Finally, Teachers Advisors LLC boosted its stake in Intersect ENT by 3.5% during the first quarter. Teachers Advisors LLC now owns 61,858 shares of the medical equipment provider’s stock valued at $1,061,000 after buying an additional 2,084 shares during the period. 86.21% of the stock is owned by hedge funds and other institutional investors.

Shares of Intersect ENT Inc (XENT) opened at $30.10 on Friday. Intersect ENT Inc has a 12 month low of $9.20 and a 12 month high of $33.25.

Intersect ENT (NASDAQ:XENT) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. The company had revenue of $22.31 million for the quarter, compared to analysts’ expectations of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. Intersect ENT’s quarterly revenue was up 20.8% on a year-over-year basis. During the same period last year, the firm earned ($0.22) earnings per share. equities analysts anticipate that Intersect ENT Inc will post -0.63 EPS for the current fiscal year.

In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total transaction of $398,464.65. Following the sale, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at approximately $864,214.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $30.19, for a total value of $603,800.00. Following the completion of the sale, the insider now directly owns 525,868 shares in the company, valued at $15,875,954.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 113,838 shares of company stock worth $3,330,115. Insiders own 13.70% of the company’s stock.

Several equities research analysts recently issued reports on XENT shares. Bank of America lifted their price objective on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Zacks Investment Research downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Canaccord Genuity raised their price target on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Northland Securities restated a “hold” rating and set a $25.00 price target on shares of Intersect ENT in a research report on Friday, November 3rd. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a research report on Tuesday, November 7th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $30.88.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/campbell-co-investment-adviser-llc-takes-228000-position-in-intersect-ent-inc-xent/1740749.html.

Intersect ENT Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.